Cite
HARVARD Citation
Staehler, M. et al. (2021). First‐line pazopanib in intermediate‐ and poor‐risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial. International journal of cancer. 148 (4), pp. 950-960. [Online].